Since starting her career in gynecologic oncology in 1999, Dr. Schilder has been active in all aspects of patient care in the academic environment, with a recent venture into industry, dedicating two years to drug development and global clinical trials. She returned to academics with the continued mission of improving the lives of women afflicted with gynecologic malignancies, and views this mission as three-pronged: 1.) Exquisite clinical care of patients by offering the best clinical and surgical expertise available, including access to clinical trials; 2.) Education of medical students and residents to ensure excellent care of these women now and in the future, and 3.) Research in order to improve treatment options available for our patients not only in terms of cures and extended survival, but also related to improved quality of life.
Her academic, clinical, and research efforts have focused on improving patient quality of life, new drug development through NIH-sponsored clinical trials within the Gynecologic Oncology Group (GOG), collaborating with colleagues in multidisciplinary research, mentoring medical students, residents and fellows in independent research, and development of Phase I-III studies at Eli Lilly & Co. She has served on the Ovarian Committee and the Gynecologic Oncology Committee for the GOG, the Breast Cancer Committee for the Society of Gynecologic Oncologists, and the Indiana University IRB. Within the IU Simon Cancer Center, she served on the Scientific Review Committee, Protocol Accrual Committee, Data Safety and Monitoring Committee, and Executive Committee. On a state and local level she served as the co-chair of the Indiana Cancer Consortium Breast and Cervical Cancer Committee, and the Gynecologic Oncology Sub-Committee for the Hoosier Oncology Group. In addition, she has provided testimony regarding bills designed to improve access to care as well as efforts related to cancer prevention before our state legislature on behalf of gynecologic oncology patients. Currently she is an executive board member for the Little Red Door, a cancer agency dedicated to the quality of life of patients living with cancer.